A 28-year-old man presents to the clinic with complaints of severe, unilateral headaches that have been occurring for the past two weeks. He describes the pain as an excruciating, stabbing sensation located around his right eye. Each episode lasts about 45 minutes and occurs multiple times a day, often waking him from sleep. He also reports associated tearing, nasal congestion, and drooping of the eyelid on the same side as the headache. His neurological examination is otherwise unremarkable. Which of the following is the most likely diagnosis?
A 45-year-old woman with a history of chronic migraines presents to the clinic seeking non-pharmacologic treatment options. She reports significant photophobia during migraine episodes, which makes it difficult to work in an office environment with bright lighting. She prefers non-medication approaches to manage her symptoms. Which of the following non-pharmacologic therapies is specifically designed to reduce photophobia in migraine patients?
A 45-year-old woman presents to her neurologist with chronic, debilitating migraines that are not well-controlled with traditional therapies. She has been advised to consider a new class of medication. Question: Which of the following is a mechanism by which CGRP receptor antagonists help in managing migraines?
A 45-year-old woman with a history of migraines is interested in trying a CGRP receptor antagonist for acute migraine relief. She is concerned about potential side effects and asks about the most common adverse reactions associated with this class of medications. Question: Which of the following is a common adverse effect of CGRP receptor antagonists?
A 29-year-old man with a history of chronic migraines presents to the clinic for follow-up. He has been experiencing migraines on more than 15 days per month despite using abortive therapies. His neurologist is considering initiating a preventive treatment targeting the CGRP pathway. Question: Which of the following CGRP receptor antagonists is approved for the preventive treatment of migraines?
A 34-year-old woman with a history of episodic migraines presents to her primary care physician seeking treatment options. She reports experiencing migraines approximately six times per month, characterized by unilateral throbbing headaches accompanied by nausea and sensitivity to light. She has tried over-the-counter medications with limited relief and is interested in exploring newer therapies. Question: Which of the following medications is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine?
A 42-year-old woman with a history of episodic migraines is prescribed rimegepant for acute headache relief. She is concerned about potential side effects and asks what she might experience. Which of the following is the most common adverse effect of rimegepant?
A 38-year-old woman with frequent migraines is considering Lasmiditan as an alternative to triptans due to a history of hypertension and Raynaud’s phenomenon. She asks if she can take the medication before driving to work. The physician explains that Lasmiditan may impair alertness and reaction time. Which of the following is a key contraindication or precaution for Lasmiditan therapy?
A 32-year-old man with episodic migraines takes Lasmiditan 200 mg at the onset of a migraine while at home. Two hours later, he feels relief from the headache. Which of the following is the most common side effect of Lasmiditan?
